Literature DB >> 21921639

Risk profile in chronic kidney disease stage 3: older versus younger patients.

Natasha J McIntyre1, Richard J Fluck, Christopher W McIntyre, Maarten W Taal.   

Abstract

BACKGROUND: The prevalence of chronic kidney disease (CKD) increases with age, but its significance in older patients is uncertain and is regarded by some as part of 'normal aging'. Moreover, subjects ≥75 years are often excluded from research studies. We therefore undertook a prospective study of patients with CKD stage 3 in primary care to compare the risk profile of older versus younger subjects.
METHODS: Subjects with an estimated glomerular filtration rate (eGFR) 59-30 ml/min/1.73 m(2) on two measurements were recruited from 32 primary care practices. Medical history and demographic data were obtained and participants underwent clinical assessment as well as urine and serum biochemistry tests.
RESULTS: 1,741 participants were recruited: mean age 72.9 ± 9 years; 60% female; 98% white; 17% diabetic. Mean eGFR was 52.5 ± 10 ml/min/1.73 m(2) and 16.9% had albuminuria. Subjects ≥75 years had a significantly lower eGFR than younger subjects and a higher risk profile characterised by greater albuminuria, more arterial stiffness and higher serum uric acid levels.
CONCLUSION: Older subjects with CKD stage 3 evidenced a higher risk profile for CKD progression and cardiovascular events than younger patients. This implies that CKD is not a benign condition in all elderly patients, but further investigation is required to identify those at greatest risk who may benefit from intervention.
© 2011 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21921639     DOI: 10.1159/000329109

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  13 in total

1.  Where now for proteinuria testing in chronic kidney disease?: Good evidence can clarify a potentially confusing message.

Authors:  Simon D S Fraser; Paul J Roderick; Maarten W Taal
Journal:  Br J Gen Pract       Date:  2016-04       Impact factor: 5.386

2.  High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients.

Authors:  F B Nerbass; R Pecoits-Filho; N J McIntyre; C W McIntyre; M W Taal
Journal:  Eur J Clin Nutr       Date:  2014-10-08       Impact factor: 4.016

3.  Treatment needs and diagnosis awareness in primary care patients with chronic kidney disease.

Authors:  Natasha J McIntyre; Richard Fluck; Chris McIntyre; Maarten Taal
Journal:  Br J Gen Pract       Date:  2012-04       Impact factor: 5.386

Review 4.  CKD: A Call for an Age-Adapted Definition.

Authors:  Pierre Delanaye; Kitty J Jager; Arend Bökenkamp; Anders Christensson; Laurence Dubourg; Bjørn Odvar Eriksen; François Gaillard; Giovanni Gambaro; Markus van der Giet; Richard J Glassock; Olafur S Indridason; Marco van Londen; Christophe Mariat; Toralf Melsom; Olivier Moranne; Gunnar Nordin; Runolfur Palsson; Hans Pottel; Andrew D Rule; Elke Schaeffner; Maarten W Taal; Christine White; Anders Grubb; Jan A J G van den Brand
Journal:  J Am Soc Nephrol       Date:  2019-09-10       Impact factor: 10.121

5.  Anthropomorphic measurements that include central fat distribution are more closely related with key risk factors than BMI in CKD stage 3.

Authors:  Philip D Evans; Natasha J McIntyre; Richard J Fluck; Christopher W McIntyre; Maarten W Taal
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

6.  The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease.

Authors:  Lakhvir K Assi; Natasha McIntyre; Simon Fraser; Scott Harris; Colin A Hutchison; Chris W McIntyre; Paul Cockwell; Maarten W Taal
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

7.  Chronic Kidney Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study.

Authors:  Adam Shardlow; Natasha J McIntyre; Richard J Fluck; Christopher W McIntyre; Maarten W Taal
Journal:  PLoS Med       Date:  2016-09-20       Impact factor: 11.069

8.  Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.

Authors:  Adam Shardlow; Natasha J McIntyre; Richard J Fluck; Christopher W McIntyre; Maarten W Taal
Journal:  BMJ Open       Date:  2017-08-23       Impact factor: 2.692

9.  Determinants of arterial stiffness in chronic kidney disease stage 3.

Authors:  Natasha J McIntyre; Richard J Fluck; Christopher W McIntyre; Apostolos Fakis; Maarten W Taal
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

10.  The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol.

Authors:  Stephanie Stringer; Praveen Sharma; Mary Dutton; Mark Jesky; Khai Ng; Okdeep Kaur; Iain Chapple; Thomas Dietrich; Charles Ferro; Paul Cockwell
Journal:  BMC Nephrol       Date:  2013-04-25       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.